| Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer H Jia, X Shen, Y Guan, M Xu, J Tu, M Mo, L Xie, J Yuan, Z Zhang, S Cai, ... Radiotherapy and Oncology 128 (3), 548-556, 2018 | 48 | 2018 |
| Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer J Zhu, X Li, Y Shen, Y Guan, W Gu, P Lian, W Sheng, S Cai, Z Zhang Radiotherapy and Oncology 129 (1), 143-148, 2018 | 17 | 2018 |
| Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience Y Guan, J Xiong, M Pan, W Shi, J Li, H Zhu, X Gong, C Li, G Mei, X Liu, ... BMC cancer 21 (1), 1-8, 2021 | 16 | 2021 |
| Hypofractionated radiosurgery plus bevacizumab for locally recurrent brain metastasis with previously high-dose irradiation Y Guan, C Wang, H Zhu, J Li, W Xu, L Sun, L Pan, J Dai, Y Wang, E Wang, ... World Neurosurgery 133, e252-e258, 2020 | 10 | 2020 |
| An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1* 1* 1 genotype Y Guan, Y Shen, Y Xu, C Li, J Wang, W Gu, P Lian, D Huang, S Cai, ... Therapeutic Advances in Gastroenterology 12, 1756284819852293, 2019 | 10 | 2019 |
| Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002) J Wang, Y Guan, W Gu, S Yan, J Zhou, D Huang, T Tong, C Li, S Cai, ... Radiation Oncology 14 (1), 1-9, 2019 | 9 | 2019 |
| Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report Y Guan, J Li, X Gong, H Zhu, C Li, G Mei, X Liu, L Pan, J Dai, Y Wang, ... Brain sciences 12 (4), 471, 2022 | 5 | 2022 |
| GRECCAR2 trial: details worthy of more attention H Jia, Y Guan, J Zhu The Lancet 391 (10116), 122, 2018 | 2 | 2018 |
| A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed … Y Guan, M Pan, J Yang, Q Lu, L Han, Y Liu, J Li, H Zhu, X Gong, G Mei, ... BMC cancer 22 (1), 1-7, 2022 | 1 | 2022 |
